Divis Laboratories receives Import Alert from USFDA for Visakhapatnam facility

21 Mar 2017 Evaluate

Divis Laboratories has received an Import Alert 66-40 from US Food and Drug Administration (USFDA) for its products manufactured at the company’s Unit-II located at Visakhapatnam, Andhra Pradesh on March 20, 2017.

The agency has exempted the following products from the Import Alert – Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate, 2, 4-wing active ester. The company along with third party consultants is currently working to address the concerns of the USFDA and is making all efforts to fully meet the compliance requirements.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.


Divis Lab Share Price

6473.35 2.75 (0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×